Oncopeptides AB (LTS:0RN4)
kr 1.654 0 (0%) Market Cap: 349.01 Mil Enterprise Value: 216.16 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 54/100

Q4 2022 Oncopeptides AB Earnings Call Transcript

Feb 16, 2023 / 08:00AM GMT
Release Date Price: kr7.22 (-4.11%)
Operator

Welcome to Oncopeptides Q4 Report for 2022. (Operator Instructions)

Now I will hand the conference over to Monica Shaw, CEO; Holger Lembrer, CFO; and Jakob Lindberg, CSO. Please go ahead.

Monica Shaw;publ;CEO
Oncopeptides AB

()-

Good morning, everybody. I'm delighted to welcome you all to my first webcast as Oncopeptides CEO. I'm Dr. Monica Shaw and I started at Oncopeptides January this year. I was delighted to join a company that has a real impact on patients in multiple myeloma. My background is as a physician, I've practiced for 5 years in the NHS in the U.K. and for the last 17 years I've been working in the industry. One of my key drivers is launching new products and I've launched over 15 across my career including for such companies such as Shire, GSK, Novartis across multiple geographies and multiple therapy areas. But multiple myeloma has always had a special place in my heart mainly because my father passed away from multiple myeloma nearly 10 years now and I'm amazed by the advances that I see in this field.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot